WO2017176958A1 - Monofunctional intermediates for ligand-dependent target protein degradation - Google Patents

Monofunctional intermediates for ligand-dependent target protein degradation Download PDF

Info

Publication number
WO2017176958A1
WO2017176958A1 PCT/US2017/026275 US2017026275W WO2017176958A1 WO 2017176958 A1 WO2017176958 A1 WO 2017176958A1 US 2017026275 W US2017026275 W US 2017026275W WO 2017176958 A1 WO2017176958 A1 WO 2017176958A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
optionally substituted
hydrogen
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/026275
Other languages
English (en)
French (fr)
Inventor
Shaomeng Wang
Yangbing Li
Angelo AGUILAR
Bing Zhou
Jiantao HU
Fuming XU
Chong QIN
Yang Hu
Weiguo XIANG
Rohan REJ
Jiuling YANG
Xin Han
Longchuan Bai
Chao-Yie Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3020281A priority Critical patent/CA3020281A1/en
Priority to US16/091,544 priority patent/US10759808B2/en
Priority to EP17718291.2A priority patent/EP3440082A1/en
Priority to JP2018552788A priority patent/JP7001614B2/ja
Priority to AU2017246453A priority patent/AU2017246453A1/en
Priority to CN201780035311.3A priority patent/CN109311900A/zh
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of WO2017176958A1 publication Critical patent/WO2017176958A1/en
Anticipated expiration legal-status Critical
Priority to US17/007,191 priority patent/US20210002289A1/en
Priority to AU2021232732A priority patent/AU2021232732A1/en
Priority to JP2021210079A priority patent/JP2022050469A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present disclosure provides compounds that are medically useful, e.g., as immunomodulators for the treatment of cancer, and/or synthetically useful as monofunctional intermediates for the preparation of small-molecule drug conjugates.
  • Coupling the monofunctional synthetic intermediates of this disclosure with an inhibitor of a target protein of interest e.g., an oncogenic protein inhibitor, e.g., a BET bromodomain inhibitor or MDM2 inhibitor, provides a heterobifunctional small-molecule that simultaneously binds the target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target protein.
  • Phthalimide-based drugs e.g., thalidomide or lenalidomide
  • protein-degradation machinery e.g., cereblon (CRBN; part of an ubiquitin E3 ligase complex). This may promote the recruitment of two transcription factors (IKZF1 and IKZF3) that are essential to disease progression, resulting in drug-induced ubiquitylation and degradation by the proteasome.
  • IKZF1 and IKZF3 two transcription factors
  • the present disclosure provides compounds having any one of
  • Compounds of the Disclosure comprise a ligand for an E3 ubiquitin ligase protein and thus can be used as an immunomodulatory drug to treat cancer, e.g., multiple myeloma, and other diseases responsive to inducing, enhancing, or suppressing an immune response, e.g., Crohn's disease, sarcoidosis, graft- versus-host disease, and rheumatoid arthritis, in a subject in need thereof.
  • cancer e.g., multiple myeloma
  • other diseases responsive to inducing, enhancing, or suppressing an immune response e.g., Crohn's disease, sarcoidosis, graft- versus-host disease, and rheumatoid arthritis
  • the present disclosure provides Compounds of the Disclosure as monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • heterobifunctional protein degraders having any one of Formulae VII-IX or XI-XXXII, below, and the pharmaceutically acceptable salts or solvates thereof.
  • Heterobifunctional protein degraders comprise a target protein inhibitor, a linker, and a ligand for an E3 ubiquitin ligase protein.
  • Compounds of the Disclosure are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • Compounds of the Disclosure are compounds represented by
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is absent
  • A is heteroarylenyl
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r is 0, 1, 2 or 3;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein.
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • Compounds of the Disclosure are compounds represented by
  • Compounds of the Disclosure are compounds represented by
  • Compounds of the Disclosure are compounds having
  • B is selected from the group consisting of:
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16d is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds having
  • R 5 is partially or entirely enriched with an isotope of hydrogen, e.g., R 5 is about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% deuterium.
  • Compounds of the Disclosure are compounds having
  • B is selected from the group consisting of:
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • L is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 ) 2 CH 2 -, -CH 2 (CH 2 ) 3 CH 2 -, - CH 2 (CH 2 ) 4 CH 2 -, -CH 2 (CH 2 ) 5 CH 2 -, and -CH 2 (CH 2 ) 6 CH 2 -.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • L is -(CH 2 ) o O-(CH 2 CH 2 0) p -(CH 2 ) q -;
  • o is 1, 2, or 3;
  • p is 0, 1, 2, 3, 4, or 5;
  • q is 1, 2, or 3.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n - and A is absent.
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n -, A is absent, and W is phenylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n -, A is absent, and W is 5-membered heteroarylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having
  • L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 )m-W-(CH 2 )n-, A is absent, and W is 6-membered heteroarylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 )m-W-(CH 2 )n-, A is absent, and W is heterocyclenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n -, A is absent, and W is cycloalkylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • L is -A-(CH 2 ) m -W-(CH 2 ) expect-;
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n - and W is phenylenyl.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n - and W is heterocyclenyl.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n - and W is cycloalkylenyl.
  • Compounds of the Disclosure are compounds having
  • A is a 5-membered heteroarylenyl selected from the group consisting of:
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -A-(CH2) m -W-(CH2) n - and A is a 6-membered heteroarylenyl.
  • A is:
  • Compounds of the Disclosure are compounds having
  • L is -(CH 2 ) r -W-(CH2)u-0-(CH 2 )v-;
  • r is 0, 1, or 2;
  • u is 1, 2, or 3;
  • v is 1, 2, or 3.
  • Compounds of the Disclosure are compounds having
  • Formula I and the salts or solvates thereof, wherein L is -(CH 2 ) r -W-(CH 2 ) u -0-(CH 2 ) v - and W is selected from the group consisting of phenylenyl and heteroarylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds having
  • Y is -C ⁇ C-.
  • Y is -CH 2 -.
  • Y is -0-.
  • Y is -N(H)-.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • B is B-la
  • Compounds of the Disclosure are compounds having
  • B is B-la
  • R 16b is selected from the group consisting of hydrogen and halo.
  • Compounds of the Disclosure are compounds having
  • B is B-la
  • R 16c is selected from the group consisting of hydrogen and halo.
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds having
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • R c , R , R e , and R are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein B is B-2a
  • Compounds of the Disclosure are compounds represented by Formula II:
  • R 5 is hydrogen.
  • Z is -CH 2 -.
  • Compounds of the Disclosure are compounds represented by Formula III:
  • Compounds of the Disclosure are compounds represented by Formula Ilia: Ilia,
  • Compounds of the Disclosure are compounds represented by Formula IV:
  • Y is selected from the group consisting of -C ⁇ C-, -0-, and -N(H)-.
  • Y is absent.
  • Y is -C ⁇ C-.
  • Compounds of the Disclosure are compounds represented by Formula V:
  • [0154] B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl; and [0174] R c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula VI:
  • [0176] B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R is selected from the group consisting of hydrogen, methyl, and fluoro;
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula Via:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula VIb:
  • X is selected from the group consisting of -C ⁇ C-, -0-, and -N(R 2a )-:
  • R 2a is selected from the group consisting of hydrogen and Ci_ 4 alkyl
  • [0221] B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-IV, and the pharmaceutically acceptable salts or solvates
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is Ci_i 2 alkylenyl.
  • L is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 )2CH2-, -CH 2 (CH 2 ) 3 CH 2 -, -CH 2 (CH 2 ) 4 CH 2 -, -CH 2 (CH 2 ) 5 CH 2 -, and -CH 2 (CH 2 ) 6 CH 2 -.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is 3- to 20-membered heteroalkylenyl.
  • L is selected from the group consisting of -(CH 2 ) o O-(CH 2 CH 2 0) p -(CH 2 ) q - and -(CH 2 )rO-(CH 2 ) s -0(CH 2 ) t -; wherein o is 2 or 3; p is 0, 1, 2, 3, 4, 5, 6, or 7; q is 2 or 3; r is 2, 3, or 4; s is 3, 4, or 5; and t is 2 or 3. In another embodiment, L is selected from the group consisting of
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is -(CH 2 ) m -W-(CH 2 ) n --
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, or VIb , and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-; and [0254] R 6 is selected from the group consisting of hydrogen and Ci_ 4 alkyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I- VI, Via, orVIb, and the pharmaceutically acceptable salts or solvates thereof wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are any one or more of the compounds of Table 1, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 2, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 3, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 4, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 5, and salts and solvates thereof.
  • Table 5
  • the disclosure provides a method of preparing a compound having Formula IX:
  • T is a monovalent radical of a target protein inhibitor
  • X, L, Y, and B are as defined in connection with Formula I.
  • the disclosure provides a method of preparing a compound having Formula IX:
  • T is a monovalent radical of a target protein inhibitor
  • X, L, Y, and B are as defined in connection with Formula I, the method comprising condensing a compound having Formula I, with compound having Formula X:
  • T is a monovalent radical of a target protein inhibitor
  • LG is a leaving group, e.g., -CI, -Br, -I, -OTs, -OMs.
  • the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, comprising:
  • [0269] B is selected from the group consisting of:
  • X is selected from the group consisting of -C ⁇ C-, -0-, -N(R 2a ) -, [0271] wherein the - and the -O- of is attached to L
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is absent
  • A is heteroarylenyl
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r is 0, 1, 2 or 3;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • [0285] B is selected from the group consisting of:
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl,
  • T is a monovalent radical of a target protein inhibitor
  • LG is a leaving group, e.g., -CI, -Br, -I, -OTs, -OMs,
  • the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, wherein the compound having Formula I are not any one of the compounds of Table 6, or any stereoisomer thereof.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is -C ⁇ C-.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is -N(H)-.
  • the disclosure provides a method of preparing a compound having Formula IX, and solvates thereof, wherein X is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 ) 2 CH 2 -, -CH 2 (CH 2 ) 3 CH 2 -, -CH 2 (CH 2 ) 4 CH 2 -, -CH 2 (CH 2 ) 5 CH 2 -, and -CH 2 (CH 2 ) 6 CH 2 -.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is 3- to 12-membered heteroalkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is -(CH 2 ) 0 0-(CH 2 CH 2 0) p -(CH 2 ) q -;
  • o is 1, 2, or 3;
  • p is 0, 1, 2, 3, 4, or 5;
  • q is 1, 2, or 3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing compound having Formula IX, and the salts or solvates thereof, wherein L -A-(CH 2 ) m -W-(CH 2 ) n -, A is absent, and W is 5-membered heteroarylenyl.
  • the disclosure provides a method of preparing compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is -A-(CH 2 ) m -W-(CH 2 ) expect-;
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula XX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-;
  • R 6 is selected from the group consisting of hydrogen and Ci_ 4 alkyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the roup consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m -W-(CH 2 ) n - and W is cycloalkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2) m -W-(CH2)n- and A is a 5-membered heteroarylenyl.
  • A is a 5-membered heteroarylenyl selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2) m -W-(CH2)n- and A is a 6-membered heteroarylenyl.
  • A is:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is -(CH 2 ) r -W-(CH2)u-0-(CH 2 )v-;
  • r is 0, 1, or 2;
  • u is 1, 2, or 3;
  • v is 1, 2, or 3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -(CH 2 ) r -W-(CH 2 ) u -0-(CH 2 ) v - and W is selected from the group consisting of phenylenyl and heteroarylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, and -N(R 2c )-.
  • Y is -C ⁇ C-.
  • Y is -CH 2 -.
  • Y is -0-.
  • Y is -N(H)-.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-la.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • B is B-la
  • R 16a is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • B is B-la
  • R 16b is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • B is B-la
  • R 16c is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-la and
  • Z is -CH 2 -.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-la and R 5 is hydrogen.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B-3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of an oncogenic protein inhibitor.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a MDM2 protein inhibitor.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a BET bromodomain protein inhibitor.
  • the disclosure provides methods of making a compound having Formula VII:
  • T is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R is a leaving group, e.g., R is selected from the group consisting of -CI and -OH,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen and fluoro
  • the disclosure provides methods of making a compound having Formula VII, or a pharmaceutically acceptable salt or solvate thereof, the method comprising:
  • R lla , R llb , R llc , and R lld are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R 12a and R 12b are independently selected from the group consisting of hydrogen and Ci-6 alkyl; or [0416] R a and R taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl; and
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • the disclosure provides methods of making a compound having Formula VIII:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8
  • R lla , R llb , R llc , and R lld are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R 12a and R 12b are independently selected from the group consisting of hydrogen and Ci_6 alkyl; or
  • R 12a and R 12b taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • the disclosure provides methods of making a compound having Formula XI:
  • R 1 is selected from the group consisting of hydrogen and optionally substituted
  • R 2a and R 2b are each independently selected from the group consisting of hydrogen, optionally substituted Ci_ 4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a and R 2b together with the carbon atom to which they are attached form a 3- to
  • R 3a and R 3b are each independently selected from the group consisting of hydrogen and optionally substituted Ci_ 4 alkyl; or
  • R 3a and R 3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl
  • R 6a and R 6b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or
  • R 6a and R 6b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R 7d is selected from the group consisting of hydrogen, optionally substituted
  • R is selected from the group consisting of optionally substituted Ci_ 4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8b is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R c is selected from the group consisting of optionally substituted Ci_ 4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R 9 selected from the group consisting of hydrogen, optionally substituted
  • Y 1 is selected from the group consisting of -0-, -S-, and -NR 10 -;
  • R 11 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 12 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 13 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 14a and R 14b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R 14a and R 14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • — y is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R 15 ;
  • R 15 is selected from the group consisting of hydrogen, halogen, Ci_ 4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • A is absent
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y 1 is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • X 1 is selected from the group consisting of Br and I;
  • R 1 is selected from the group consisting of hydrogen and optionally substituted
  • R 2a and R 2b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a and R 2b together with the carbon atom to which they are attached form a 3- to
  • R 3a and R 3b are each independently selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl; or
  • R 3a and R 3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl
  • R 6a and R 6b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or [0501] R a and R taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R is selected from the group consisting of hydrogen, optionally substituted
  • R is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8b is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8c is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R 9 selected from the group consisting of hydrogen, optionally substituted
  • Y 1 is selected from the group consisting of -0-, -S-, and -NR 10 -;
  • R 11 is selected from the group consisting of optionally substituted Ci_ 6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 12 is selected from the group consisting of optionally substituted Ci_ 6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 13 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C3- 12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 14a and R 14b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R 14a and R 14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • y is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R 15 ;
  • R 15 is selected from the group consisting of hydrogen, halogen, Ci_ 4 alkyl, and alkoxy,
  • [0518] B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl, and
  • the disclosure provides a method for making a compound represented by Formula XIII:
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 3a and R 3b are hydrogen.
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 1 is C 1-4 alkyl. In another embodiment, R 1 is methyl, or a pharmaceutically acceptable salt or hydrate thereof.
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 2a and R 2b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method for making a compound represented by Formula XIV:
  • the disclosure provides a method or making a compound represented by Formula XV:
  • R 2a is Ci_ 4 alkyl
  • R 4 , L, Y, Y 1 , and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by Formula XVI:
  • R 2a is Ci_ 4 alkyl
  • R 4 , L, Y, Y 1 , and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 4 is selected from the group consisting of halogen, Ci_ 4 alkyl, optionally C 2 _ 4 alkenyl, optionally substituted C 2 _ 4 alkynyl, aralkyl, optionally substituted C 6 -i 4 aryl, optionally substituted C 3 _i 2 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl.
  • R 4 is aralkyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, Y 1 is -0-. In another embodiment, Y 1 is -N(H)-.
  • the disclosure provides a method for making a compound represented by Formula XVII:
  • R 2a is selected from the group consisting of hydrogen and Ci_ 3 alkyl
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen, Ci_ 4 alkyl, haloalkyl, Ci_ 4 alkoxy, and halo
  • L, Y, and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is CM 2 alkylenyl.
  • L is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 ) 2 CH 2 -, -CH 2 (CH 2 ) 3 CH 2 -, -CH 2 (CH 2 ) 4 CH 2 -, -CH 2 (CH 2 ) 5 CH 2 -, and -CH 2 (CH 2 ) 6 CH 2 -.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein, L is 3- to 12-membered heteroalkylenyl.
  • L is -(CH 2 ) 0 0-(CH 2 CH 2 0) p -(CH 2 ) q -; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • the disclosure provides methods for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of: -CH 2 OCH 2 CH 2 -, -CH 2 CH 2 OCH 2 CH 2 -, -CH 2 0(CH 2 CH 2 0)CH 2 CH 2 - -CH 2 0(CH 2 CH 2 0) 2 CH 2 CH 2 -, ⁇ 2 0 ⁇ 3 ⁇ 4 ⁇ 2 0 ⁇ 3 ⁇ 4 ⁇ 2 -, -CH 2 CH20(CH2CH20)6CH 2 CH2-, -CHsCHsCKCF CF C eCF CF -, -CH2CH2CH2OCH2CH2OCH2CH2CH2-, -CH2CH2CH20(CH2CH20)2CH2CH 2 CH2-, and -CH 2 CH 2 CH 2 0(CH 2 ) 4 OCH 2 CH 2 CH 2 -.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is -(CH 2 )m-W-(CH 2 ) n -.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is -(CH 2 ) m -W-(CH 2 ) u - 0-(CH 2 )v".
  • W is phenylenyl.
  • W is 5- membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • n 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-; and R 6 is selected from the group consisting of hydrogen and Ci_ 4 alkyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • L is L-3.
  • L is L-4.
  • L is L-5.
  • L is L-6.
  • L is L-7.
  • L is L-8.
  • L is L-9.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • L is L-10. In another embodiment, L is L- 11. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • the disclosure provides a method for making a compound represented by Formula XVIII: XVIII,
  • the disclosure provides a method for making a compound represented by Formula XIX:
  • the disclosure provides a method for making a compound represented by Formula XX:
  • the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein R 2a is hydrogen. In another embodiment, R 2a is methyl.
  • the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, and -N(H)-.
  • Y is -C ⁇ C-.
  • Y is -CH 2 -.
  • Y is -0-.
  • Y is -N(H)-.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, wherein B is B-la.
  • Z is -CH 2 -.
  • R 5 is hydrogen.
  • B-la is selected from the roup consisting of:
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • the disclosure provides a method of making a compound having Formula XXI:
  • R 1 is selected from the group consisting of hydrogen and optionally substituted
  • R 2a and R 2b are each independently selected from the group consisting of hydrogen, optionally substituted Ci_ 4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a and R 2b together with the carbon atom to which they are attached form a 3- to
  • R is selected from the group consisting of optionally substituted C 6 -i 4 aryl and optionally substituted 5- to 14-membered heteroaryl
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2 _ 4 alkenyl, optionally substituted C 2 _ 4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • — is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R 15 ;
  • R 15 is selected from the group consisting of hydrogen, halogen, Ci_ 4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • A is absent
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl,
  • X 1 is selected from the group consisting of -Br and -I;
  • R 1 is selected from the group consisting of hydrogen and optionally substituted
  • R 2a and R 2b are each independently selected from the group consisting of hydrogen, optionally substituted Ci_ 4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a and R 2b together with the carbon atom to which they are attached form a 3- to
  • R is selected from the group consisting of optionally substituted C 6 -i 4 aryl and optionally substituted 5- to 14-membered heteroaryl;
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2 _ 4 alkenyl, optionally substituted C 2 _ 4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3 _i 2 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • ⁇ — is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R 15 ;
  • R 15 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and alkoxy,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl,
  • A is selected from the group consisting of 5-membered heteroarylenyl and
  • A is absent;
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16b is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl;
  • R 16c is selected from the group consisting of hydrogen, halo, and Ci_ 4 alkyl, and
  • the disclosure provides a method for making a compound represented by Formula XXIII
  • Formula XXI wherein R 1 , R 2 a 1 , R 2b' , R 3 , R 4 , L, Y, and B are as defined in connection with Formula XXI.
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R is optionally substituted phenyl.
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 1 is C 1-4 alkyl. In another embodiment, R 1 is methyl.
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 2a and R 2b are each independently selected from the group consisting of hydrogen and Ci_ 4 alkyl.
  • the disclosure provides a method for making a compound represented by Formula XXIV:
  • the disclosure provides a method for making a compound represented by Formula XXV:
  • R 2a is Ci_ 4 alkyl
  • R 3 R 4 , L, Y, and B are as defined in connection with Formula XXI.
  • the disclosure provides a method for making a compound represented by Formula XXVI:
  • Formula XXI wherein R 2a is Ci_ 4 alkyl, and R 3 , R 4 , L, Y, and B are as defined in connection with Formula XXI.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI, or XXIII-XXVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 4 is Ci_ 4 alkyl. In another embodiment, R 4 is methyl. In another embodiment, R 4 is hydrogen.
  • the disclosure provides a method for making a compound represented by Formula XXVII:
  • R 2a is selected from the group consisting of hydrogen and Ci_ 3 alkyl
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen, Ci_ 4 alkyl, haloalkyl, Ci_ 4 alkoxy, and halo
  • L, Y, and B are as defined in connection with Formula XXI.
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • L is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 (CH 2 ) 2 CH 2 -, -CH 2 (CH 2 ) 3 CH 2 -, -CH 2 (CH 2 ) 4 CH 2 -, -CH 2 (CH 2 ) 5 CH 2 -, and - CH 2 (CH 2 ) 6 CH 2 -.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein, L is 3- to 12-membered heteroalkylenyl.
  • L is -(CH 2 ) o O-(CH 2 CH 2 0) p -(CH 2 ) q -; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of: - CH 2 OCH 2 CH 2 -, -CH 2 CH 2 OCH 2 CH 2 -, -CH 2 0(CH 2 CH 2 0)CH 2 CH 2 -,
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is -(CH 2 ) m -W-(CH 2 ) n -.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is -(CH 2 ) m -W-(CH 2 ) u -0-(CH 2 ) v -.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of -0-, -S-, and -N(R 6 )-; and R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • n is 2, 3, or 4.
  • L is L-3.
  • L is L-4.
  • L is L-5.
  • L is L-6.
  • L is L-7.
  • L is L-8.
  • L is L-9.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acce table salts or solvates thereof, wherein L is selected from the group consisting of:
  • m is 0. In another embodiment, n is 1, 2, 3, 4, or 5. In another embodiment, n is 2, 3, or 4. In another embodiment, L is L-10. In another embodiment, L is L-l 1. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is -(CH 2 ) m -W-(CH 2 ) u -0-(CH 2 ) v -; W is selected from the group consisting of 5-membered heteroarylenyl and optionally substituted 6-membered heteroarylenyl; m is 0, 1, 2, 3, 4, 5, 6, or 7; u is 0; and v is 1, 2, 3, or 4. In another embodiment, m is 0.
  • the disclosure provides a method for making a compound represented by Formula XXVIII:
  • the disclosure provides a method for making a compound represented by Formula XXIX:
  • the disclosure provides a method for making a compound represented by Formula XXX:
  • the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein R 2a is hydrogen. In another embodiment, R 2a is methyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of -C ⁇ C-, -CH 2 - , -0-, and -N(H)-.
  • Y is -C ⁇ C-.
  • Y is - CH 2 -.
  • Y is -0-.
  • Y is -N(H)-.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-la.
  • Z is -CH 2 -.
  • R 5 is hydrogen.
  • B-la is selected from the group consisting of:
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • the disclosure provides methods of making a compound having Formula XXXI
  • B is selected from the group consisting of:
  • R a is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and -N(H)R 3c ;
  • R 3c is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of -C ⁇ C-, -CH 2 -, -0-, -N(R 2c )-,
  • R 2c , R 2d , R 2 ⁇ , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • R 5 is selected from the group consisting of hydrogen and fluoro
  • R la is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and -N(H)R ;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/US2017/026275 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation Ceased WO2017176958A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US16/091,544 US10759808B2 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
EP17718291.2A EP3440082A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
JP2018552788A JP7001614B2 (ja) 2016-04-06 2017-04-06 リガンド依存性の標的タンパク質分解のための単官能性中間体
AU2017246453A AU2017246453A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
CN201780035311.3A CN109311900A (zh) 2016-04-06 2017-04-06 用于配体依赖性靶蛋白质降解的单官能中间体
CA3020281A CA3020281A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
US17/007,191 US20210002289A1 (en) 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation
AU2021232732A AU2021232732A1 (en) 2016-04-06 2021-09-15 Monofunctional intermediates for ligand-dependent target protein degradation
JP2021210079A JP2022050469A (ja) 2016-04-06 2021-12-24 リガンド依存性の標的タンパク質分解のための単官能性中間体

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662318974P 2016-04-06 2016-04-06
US62/318,974 2016-04-06
US201662321499P 2016-04-12 2016-04-12
US62/321,499 2016-04-12
US201662393935P 2016-09-13 2016-09-13
US201662393888P 2016-09-13 2016-09-13
US201662393874P 2016-09-13 2016-09-13
US62/393,935 2016-09-13
US62/393,888 2016-09-13
US62/393,874 2016-09-13
US201662409571P 2016-10-18 2016-10-18
US201662409592P 2016-10-18 2016-10-18
US62/409,571 2016-10-18
US62/409,592 2016-10-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/091,544 A-371-Of-International US10759808B2 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
US17/007,191 Continuation US20210002289A1 (en) 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation

Publications (1)

Publication Number Publication Date
WO2017176958A1 true WO2017176958A1 (en) 2017-10-12

Family

ID=58549317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/026275 Ceased WO2017176958A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation

Country Status (7)

Country Link
US (2) US10759808B2 (enExample)
EP (1) EP3440082A1 (enExample)
JP (2) JP7001614B2 (enExample)
CN (1) CN109311900A (enExample)
AU (2) AU2017246453A1 (enExample)
CA (1) CA3020281A1 (enExample)
WO (1) WO2017176958A1 (enExample)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144789A1 (en) * 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CN109963853A (zh) * 2017-09-03 2019-07-02 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US10414755B2 (en) 2017-08-23 2019-09-17 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110357850A (zh) * 2018-03-26 2019-10-22 广东东阳光药业有限公司 一种含硫杂环化合物的制备方法
WO2019242625A1 (zh) * 2018-06-20 2019-12-26 上海科技大学 制备来那度胺衍生物的方法
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN110963994A (zh) * 2018-09-30 2020-04-07 中国科学院上海药物研究所 异吲哚啉类化合物、其制备方法、药物组合物及用途
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
WO2020073930A1 (zh) 2018-10-09 2020-04-16 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
US10646575B2 (en) 2016-05-10 2020-05-12 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US10660968B2 (en) 2016-05-10 2020-05-26 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020114482A1 (zh) * 2018-12-06 2020-06-11 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US10844039B2 (en) 2018-11-13 2020-11-24 Biotheryx, Inc. Substituted isoindolinones
US10849982B2 (en) 2016-05-10 2020-12-01 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2021502386A (ja) * 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
US20210054020A1 (en) * 2018-02-13 2021-02-25 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021119571A1 (en) * 2019-12-12 2021-06-17 Biotheryx, Inc. Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
CN112979657A (zh) * 2021-02-03 2021-06-18 福建医科大学 一种靶向降解Hsp90蛋白的化合物及其制备方法与应用
WO2021130682A2 (en) 2019-12-23 2021-07-01 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
WO2021198966A1 (en) * 2020-03-31 2021-10-07 Orum Therapeutics, Inc. Conjugates
WO2021205391A1 (zh) 2020-04-09 2021-10-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11185537B2 (en) 2018-07-10 2021-11-30 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11254672B2 (en) 2017-09-04 2022-02-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
WO2022042707A1 (en) * 2020-08-27 2022-03-03 Cullgen (Shanghai) , Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
WO2022043930A2 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
AU2017367872B2 (en) * 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US20220117982A1 (en) * 2018-04-09 2022-04-21 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11401256B2 (en) 2017-09-04 2022-08-02 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
US11459335B2 (en) 2017-06-20 2022-10-04 C4 Therapeutics, Inc. N/O-linked Degrons and Degronimers for protein degradation
US20220313829A1 (en) * 2019-08-05 2022-10-06 Shanghaitech University Egfr protein degradant and anti-tumor application thereof
US11466028B2 (en) * 2016-09-13 2022-10-11 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
WO2022223033A1 (zh) 2021-04-23 2022-10-27 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11524949B2 (en) 2017-11-16 2022-12-13 C4 Therapeutics, Inc. Degraders and Degrons for targeted protein degradation
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US20230096517A1 (en) * 2020-02-25 2023-03-30 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11623929B2 (en) 2018-06-04 2023-04-11 C4 Therapeutics, Inc. Spirocyclic compounds
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
EP4041736A4 (en) * 2020-01-23 2023-06-07 Ascentage Pharma (Suzhou) Co., Ltd. AMORPHOUS FORM OR CRYSTALLINE FORM OF 2-INDOLINOLINOLOLYLSPIRONONE COMPOUNDS OR THEIR SALTS, SOLVENT COMPLEXES
RU2797559C2 (ru) * 2018-07-10 2023-06-07 Новартис Аг Производные 3-(5-гидрокси-1-оксоизоиндолин-2-ил) пиперидин-2,6-диона и их применение в лечении заболеваний, связанных с белком с "цинковыми пальцами" 2 (ikzf2) семейства ikaros
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
US11802131B2 (en) 2017-09-04 2023-10-31 C4 Therapeutics, Inc. Glutarimides for medical treatment
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
US11878968B2 (en) 2021-07-09 2024-01-23 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate IKZF2
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
US12048747B2 (en) 2016-05-10 2024-07-30 C4 Therapeutics, Inc. Substituted piperidine Degronimers for Target Protein degradation
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025096855A1 (en) 2023-11-02 2025-05-08 Kumquat Biosciences Inc. Degraders and uses thereof
US12310975B2 (en) 2019-10-17 2025-05-27 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12454521B2 (en) 2018-12-20 2025-10-28 C4 Therapeutics, Inc. Targeted protein degradation
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808728QA (en) * 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
UA123168C2 (uk) * 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
US10975093B2 (en) * 2016-09-13 2021-04-13 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET protein degraders
MX2021003999A (es) * 2018-10-08 2021-06-23 Univ Michigan Regents Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
CN114258392A (zh) * 2019-08-21 2022-03-29 卡尔维斯塔制药有限公司 酶抑制剂
EP4048668A4 (en) * 2019-10-21 2024-03-13 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20250236607A1 (en) * 2022-03-30 2025-07-24 Ohio State Innovation Foundation Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof
CN117285524A (zh) * 2022-06-24 2023-12-26 中国科学院上海药物研究所 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用
WO2024003749A1 (en) * 2022-06-27 2024-01-04 Pin Therapeutics, Inc. Compounds and methods for degrading casein kinase 1 alpha
WO2024051766A1 (zh) * 2022-09-08 2024-03-14 标新生物医药科技(上海)有限公司 基于cereblon蛋白设计的分子胶化合物及其应用

Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011111A1 (en) 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20020132977A1 (en) 1999-12-08 2002-09-19 Yuan Zhi-Min Inhibition of P53 degradation
US20030096841A1 (en) * 2000-12-27 2003-05-22 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6617346B1 (en) 2001-12-18 2003-09-09 Hoffmann-La Roche Inc. Cis-imidazolines
US6734302B2 (en) 2001-12-18 2004-05-11 Hoffmann-La Roche Inc. Cis-imidazolines
US20040171035A1 (en) 2002-11-08 2004-09-02 Irm Llc Methods and compositions for modulating P53 transcription factor
US20050137137A1 (en) 1996-07-05 2005-06-23 Lane David P. Inhibitors of the Interaction between p53 and MDM2
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US20050288287A1 (en) 2004-05-18 2005-12-29 Nader Fotouhi Chiral cis-imidazolines
US20060211718A1 (en) 2003-02-13 2006-09-21 Government Of The Us, As Represented By The Sec- Retary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
US20060211757A1 (en) 2005-02-22 2006-09-21 Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
US20080039472A1 (en) 2004-09-22 2008-02-14 Janssen Pharmaceutica N.V. Inhibitors of the Interaction Between Mdm2 and P53
US20080171723A1 (en) 2003-12-22 2008-07-17 John Hopkins University, Johns Hopkins Technology Transfer Boronic Acid Aryl Analogs
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008125487A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Diphenyl-dihydro-imidazopyridinones
US20080261917A1 (en) 2004-09-02 2008-10-23 Hendrika Maria Gerarda Willems Isoindolin-1-One Derivatives
US20080280769A1 (en) 2007-04-20 2008-11-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US20090030181A1 (en) 2004-04-06 2009-01-29 Kyou-Hoon Han Peptides for Inhibiting MDM2 Function
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009037343A1 (en) 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
US20090149493A1 (en) 2006-03-22 2009-06-11 Jean Fernand Armand Lacrampe Inhibitors of the interaction between mdm2 and p53
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
US20090227542A1 (en) 2002-06-13 2009-09-10 Johns Hopkins University, Johns Hopkins Technology Transfer Novel Boronic Chalcone Derivatives and Uses Thereof
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
US20090312310A1 (en) 2006-12-14 2009-12-17 Haruko Kawato Imidazothiazole derivatives
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009156735A2 (en) 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
WO2010123975A1 (en) 2009-04-22 2010-10-28 Resverlogix Corp. Novel anti-inflammatory agents
WO2011054848A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2011054843A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases
WO2011054844A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Condensed azepine derivatives as bromodomain inhibitors
WO2011054846A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors
WO2011054845A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143669A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions and methods for treating neoplasia, inflammatory disease and other disorders
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
WO2012075383A2 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012116170A1 (en) 2011-02-23 2012-08-30 Ming-Ming Zhou Inhibitors of bromodomains as modulators of gene expression
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013024104A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013030150A1 (de) 2011-09-01 2013-03-07 Bayer Intellectual Property Gmbh 6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013097601A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Bromodomain inhibitors
US8518984B2 (en) 2009-11-12 2013-08-27 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics
US20130281450A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
US20130331382A1 (en) 2012-06-12 2013-12-12 Abbvie Inc Pyridinone and Pyridazinone Derivatives
US20140005169A1 (en) 2010-12-02 2014-01-02 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US8680132B2 (en) 2010-11-12 2014-03-25 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US20140256706A1 (en) 2013-03-11 2014-09-11 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US20150246923A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US20150291562A1 (en) * 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002765A (es) * 2005-08-31 2008-04-07 Celgene Corp Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
CA2660806C (en) * 2006-08-30 2015-06-16 Celgene Corporation 5-substituted isoindoline compounds
RS51725B (sr) * 2006-09-15 2011-10-31 Celgene Corporation Jedinjenja n-metilaminometil izoindola i kompozicije koje ih sadrže i upotreba istih
RS56232B1 (sr) * 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
US20160282354A1 (en) * 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
ES2812877T3 (es) * 2014-10-30 2021-03-18 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Patent Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137137A1 (en) 1996-07-05 2005-06-23 Lane David P. Inhibitors of the Interaction between p53 and MDM2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
WO1998011111A1 (en) 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
US20020132977A1 (en) 1999-12-08 2002-09-19 Yuan Zhi-Min Inhibition of P53 degradation
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030096841A1 (en) * 2000-12-27 2003-05-22 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6617346B1 (en) 2001-12-18 2003-09-09 Hoffmann-La Roche Inc. Cis-imidazolines
US6734302B2 (en) 2001-12-18 2004-05-11 Hoffmann-La Roche Inc. Cis-imidazolines
US20090227542A1 (en) 2002-06-13 2009-09-10 Johns Hopkins University, Johns Hopkins Technology Transfer Novel Boronic Chalcone Derivatives and Uses Thereof
US20040171035A1 (en) 2002-11-08 2004-09-02 Irm Llc Methods and compositions for modulating P53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US20060211718A1 (en) 2003-02-13 2006-09-21 Government Of The Us, As Represented By The Sec- Retary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
US20100048593A1 (en) 2003-02-13 2010-02-25 Government of the US, as represented by the Secretary, Department of Health & Human Services Deazaflavin compounds and methods of use thereof
US7060713B2 (en) 2003-03-13 2006-06-13 Hoffmann-La Roche Inc. Substituted piperidines
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US20080171723A1 (en) 2003-12-22 2008-07-17 John Hopkins University, Johns Hopkins Technology Transfer Boronic Acid Aryl Analogs
US20090030181A1 (en) 2004-04-06 2009-01-29 Kyou-Hoon Han Peptides for Inhibiting MDM2 Function
US20050288287A1 (en) 2004-05-18 2005-12-29 Nader Fotouhi Chiral cis-imidazolines
US20090143364A1 (en) 2004-05-18 2009-06-04 Nader Fotouhi Chiral cis-imidazolines
US20080261917A1 (en) 2004-09-02 2008-10-23 Hendrika Maria Gerarda Willems Isoindolin-1-One Derivatives
US20080039472A1 (en) 2004-09-22 2008-02-14 Janssen Pharmaceutica N.V. Inhibitors of the Interaction Between Mdm2 and P53
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US20060211757A1 (en) 2005-02-22 2006-09-21 Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20090149493A1 (en) 2006-03-22 2009-06-11 Jean Fernand Armand Lacrampe Inhibitors of the interaction between mdm2 and p53
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20090312310A1 (en) 2006-12-14 2009-12-17 Haruko Kawato Imidazothiazole derivatives
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008125487A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Diphenyl-dihydro-imidazopyridinones
US20080280769A1 (en) 2007-04-20 2008-11-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
WO2009037343A1 (en) 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
US20100286127A1 (en) 2007-12-28 2010-11-11 Mitsubishi Tanabe Pharma Corporation Antitumor agent
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
WO2009156735A2 (en) 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010123975A1 (en) 2009-04-22 2010-10-28 Resverlogix Corp. Novel anti-inflammatory agents
US20120059002A1 (en) 2009-04-22 2012-03-08 Hansen Henrik C Novel anti-inflammatory agents
US20120252781A1 (en) 2009-11-05 2012-10-04 James Bailey Benzodiazepine Bromodomain Inhibitor
US8580957B2 (en) 2009-11-05 2013-11-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2011054848A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2011054846A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors
WO2011054844A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Condensed azepine derivatives as bromodomain inhibitors
US20120208800A1 (en) 2009-11-05 2012-08-16 Chun-Wa Chung Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases
WO2011054843A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases
WO2011054845A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
US20120202799A1 (en) 2009-11-05 2012-08-09 Miriam Crowe Condensed Azepine Derivatives As Bromodomain Inhibitors
US8557984B2 (en) 2009-11-05 2013-10-15 Glaxosmithkline Llc Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors
US8518984B2 (en) 2009-11-12 2013-08-27 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US20140011862A1 (en) 2010-05-14 2014-01-09 Cold Spring Harbor Laboratory Compositions and Methods for Treating Leukemia
US20130252331A1 (en) 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
WO2011143669A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions and methods for treating neoplasia, inflammatory disease and other disorders
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
US20130184264A1 (en) 2010-05-14 2013-07-18 James Elliott Bradner Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
US20130079335A1 (en) 2010-06-22 2013-03-28 James Matthew Bailey Benzotriazolodiazepine Compounds Inhibitors Of Bromodomains
US8680132B2 (en) 2010-11-12 2014-03-25 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
WO2012075383A2 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US20120157428A1 (en) 2010-12-02 2012-06-21 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US20140005169A1 (en) 2010-12-02 2014-01-02 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012116170A1 (en) 2011-02-23 2012-08-30 Ming-Ming Zhou Inhibitors of bromodomains as modulators of gene expression
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013024104A1 (en) 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013030150A1 (de) 2011-09-01 2013-03-07 Bayer Intellectual Property Gmbh 6H-THIENO[3,2-f][1,2,4]TRIAZOLO[4,3-a][1,4]DIAZEPINE
WO2013097601A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Bromodomain inhibitors
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281450A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
US20130331382A1 (en) 2012-06-12 2013-12-12 Abbvie Inc Pyridinone and Pyridazinone Derivatives
US20140256706A1 (en) 2013-03-11 2014-09-11 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US20150246923A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US20150291562A1 (en) * 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
A.L. BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604
ASHTON C. LAI ET AL: "Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 55, no. 2, 11 January 2016 (2016-01-11), pages 807 - 810, XP055388339, ISSN: 1433-7851, DOI: 10.1002/anie.201507634 *
BONDESON ET AL., NAT. CHEM. BIOL., vol. 11, 2015, pages 611 - 617
BUCKLEY ET AL., ANGEW, CHEM. INT. ED. ENGL., vol. 51, 2012, pages 11463 - 11467
BUCKLEY ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 4465 - 4468
CHENE, P., MOLECULAR CANCER RESEARCH, vol. 2, 2004, pages 20 - 28
DELMORE ET AL., CELL, vol. 146, 2011, pages 904 - 917
DING, K ET AL., J. MED. CHEM., vol. 49, 2006, pages 3432 - 3435
E.C. VAN TONDER ET AL., AAPS PHARM. SCI. TECH., vol. 5, no. 1, 2004
ITO ET AL., SCIENCE, vol. 327, 2010, pages 1345 - 1350
LIPKOWITZ; WEISSMAN, NAT REV CANCER, vol. 11, 2011, pages 629 - 643
M. CAIRA ET AL., J. PHARMACEUT. SCI., vol. 93, no. 3, 2004, pages 601 - 611
MONTALBETTI; FALQUE, TETRAHEDRON, vol. 61, 2005, pages 10827 - 10852
PAZGIER ET AL., PROC. NATL. ACAD. SCI. USA., vol. 106, 2009, pages 4665 - 4670
SEAL ET AL., BIOORG. MED. CHEM. LETT., vol. 22, 2012, pages 2968 - 2972
SHANGARY ET AL., ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 49, 2009, pages 223 - 241
SHANGARY, S ET AL., CLIN. CANCER RES., vol. 14, 2008, pages 5318 - 5324
SHANGARY, S ET AL., PROC. NATL. ACAD. SCI. USA., vol. 105, 2008, pages 3933 - 3938
STEWART S G ET AL: "New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 18, no. 2, 15 January 2010 (2010-01-15), pages 650 - 662, XP026835896, ISSN: 0968-0896, [retrieved on 20091206] *
VAN HAGEN ET AL., NUCLEIC ACIDS RESEARCH, vol. 38, 2010, pages 1922 - 1931
VASSILEV, L.T ET AL., SCIENCE, vol. 303, 2004, pages 844 - 848
VASSILEV, L.T. ET AL., SCIENCE, vol. 303, 2004, pages 844 - 848
VASSILEV, L.T., TRENDS MOL. MED, vol. 13, 2007, pages 23 - 31
WEBER, EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 20, 2010, pages 179 - 191
WINTER ET AL., SCIENCE, vol. 348, 2015, pages 1376 - 1381
WUTS, P. G. M.; GREENE, T. W.: "Greene's Protective Groups in Organic Synthesis", 2007, J. WILEY & SONS
Z. MA ET AL., TETRAHEDRON: ASYMMETRY, vol. 8, no. 6, 1997, pages 883 - 888
ZENGERLE ET AL., ACS CHEM. BIOL., vol. 10, 2015, pages 1770 - 1777

Cited By (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076405B2 (en) 2016-05-10 2024-09-03 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US10905768B1 (en) 2016-05-10 2021-02-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US10660968B2 (en) 2016-05-10 2020-05-26 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US11185592B2 (en) 2016-05-10 2021-11-30 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US12048747B2 (en) 2016-05-10 2024-07-30 C4 Therapeutics, Inc. Substituted piperidine Degronimers for Target Protein degradation
US12048748B2 (en) 2016-05-10 2024-07-30 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US10646575B2 (en) 2016-05-10 2020-05-12 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US10849982B2 (en) 2016-05-10 2020-12-01 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
US11992531B2 (en) 2016-05-10 2024-05-28 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
US11466028B2 (en) * 2016-09-13 2022-10-11 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
US11458123B2 (en) * 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
AU2017367872B2 (en) * 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US11986531B2 (en) 2016-12-23 2024-05-21 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11046709B2 (en) 2017-02-03 2021-06-29 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET bromodomain inhibitors
WO2018144789A1 (en) * 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
US12180225B2 (en) 2017-06-20 2024-12-31 C4 Therapeutics, Inc. N/O-linked degrons and degronimers for protein degradation
US11459335B2 (en) 2017-06-20 2022-10-04 C4 Therapeutics, Inc. N/O-linked Degrons and Degronimers for protein degradation
US12441740B2 (en) 2017-06-20 2025-10-14 C4 Therapeutics, Inc. N/O-linked degrons and degronimers for protein degradation
US10647701B2 (en) 2017-08-23 2020-05-12 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10640489B2 (en) 2017-08-23 2020-05-05 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11053218B2 (en) 2017-08-23 2021-07-06 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10414755B2 (en) 2017-08-23 2019-09-17 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN109963853B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN109963853A (zh) * 2017-09-03 2019-07-02 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US11254672B2 (en) 2017-09-04 2022-02-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US11787802B2 (en) 2017-09-04 2023-10-17 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US11802131B2 (en) 2017-09-04 2023-10-31 C4 Therapeutics, Inc. Glutarimides for medical treatment
US11401256B2 (en) 2017-09-04 2022-08-02 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
US12365681B2 (en) 2017-09-04 2025-07-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US12091397B2 (en) 2017-09-04 2024-09-17 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11786602B2 (en) 2017-11-10 2023-10-17 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
US12285490B2 (en) 2017-11-10 2025-04-29 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
JP2024041896A (ja) * 2017-11-10 2024-03-27 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
JP7424637B2 (ja) 2017-11-10 2024-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
JP2021502386A (ja) * 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
JP7789402B2 (ja) 2017-11-10 2025-12-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
US11524949B2 (en) 2017-11-16 2022-12-13 C4 Therapeutics, Inc. Degraders and Degrons for targeted protein degradation
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4613773A2 (en) 2017-12-26 2025-09-10 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12168057B2 (en) 2017-12-26 2024-12-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12006329B2 (en) 2018-01-12 2024-06-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20210054020A1 (en) * 2018-02-13 2021-02-25 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
US12325725B2 (en) * 2018-02-13 2025-06-10 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
US11753397B2 (en) 2018-03-26 2023-09-12 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110357850A (zh) * 2018-03-26 2019-10-22 广东东阳光药业有限公司 一种含硫杂环化合物的制备方法
JP2021519337A (ja) * 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
US12226424B2 (en) * 2018-04-09 2025-02-18 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
US20220117982A1 (en) * 2018-04-09 2022-04-21 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
US12227504B2 (en) 2018-04-16 2025-02-18 C4 Therepeutics, Inc. Spirocyclic compounds
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US11623929B2 (en) 2018-06-04 2023-04-11 C4 Therapeutics, Inc. Spirocyclic compounds
WO2019242625A1 (zh) * 2018-06-20 2019-12-26 上海科技大学 制备来那度胺衍生物的方法
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11185537B2 (en) 2018-07-10 2021-11-30 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112261970A (zh) * 2018-07-10 2021-01-22 诺华股份有限公司 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途
US11833142B2 (en) 2018-07-10 2023-12-05 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR102873348B1 (ko) 2018-07-10 2025-10-20 노파르티스 아게 3-(5-하이드록시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 ikaros 패밀리 아연 핑거 2(ikzf2)-의존성 질환의 치료에 있어서의 이의 용도
EP4306111A3 (en) * 2018-07-10 2024-04-17 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
RU2797559C2 (ru) * 2018-07-10 2023-06-07 Новартис Аг Производные 3-(5-гидрокси-1-оксоизоиндолин-2-ил) пиперидин-2,6-диона и их применение в лечении заболеваний, связанных с белком с "цинковыми пальцами" 2 (ikzf2) семейства ikaros
KR20210031680A (ko) * 2018-07-10 2021-03-22 노파르티스 아게 3-(5-하이드록시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 ikaros 패밀리 아연 핑거 2(ikzf2)-의존성 질환의 치료에 있어서의 이의 용도
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
US12459921B2 (en) 2018-09-30 2025-11-04 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, preparation method, pharmaceutical composition and use thereof
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN110963994A (zh) * 2018-09-30 2020-04-07 中国科学院上海药物研究所 异吲哚啉类化合物、其制备方法、药物组合物及用途
WO2020073930A1 (zh) 2018-10-09 2020-04-16 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
US11352338B2 (en) 2018-11-13 2022-06-07 Biotheryx, Inc. Substituted isoindolinones
JP2022507267A (ja) * 2018-11-13 2022-01-18 バイオセリックス， インコーポレイテッド 置換イソインドリノン
US10844039B2 (en) 2018-11-13 2020-11-24 Biotheryx, Inc. Substituted isoindolinones
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
US11452716B2 (en) 2018-11-23 2022-09-27 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12258341B2 (en) 2018-11-30 2025-03-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2020114482A1 (zh) * 2018-12-06 2020-06-11 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN111285850A (zh) * 2018-12-06 2020-06-16 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN111285850B (zh) * 2018-12-06 2022-04-22 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
AU2019392231B2 (en) * 2018-12-06 2022-10-20 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
US12454521B2 (en) 2018-12-20 2025-10-28 C4 Therapeutics, Inc. Targeted protein degradation
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US12077555B2 (en) 2019-04-05 2024-09-03 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US20220313829A1 (en) * 2019-08-05 2022-10-06 Shanghaitech University Egfr protein degradant and anti-tumor application thereof
US12310975B2 (en) 2019-10-17 2025-05-27 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
WO2021119571A1 (en) * 2019-12-12 2021-06-17 Biotheryx, Inc. Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021130682A2 (en) 2019-12-23 2021-07-01 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
EP4041736A4 (en) * 2020-01-23 2023-06-07 Ascentage Pharma (Suzhou) Co., Ltd. AMORPHOUS FORM OR CRYSTALLINE FORM OF 2-INDOLINOLINOLOLYLSPIRONONE COMPOUNDS OR THEIR SALTS, SOLVENT COMPLEXES
EP4112614A4 (en) * 2020-02-25 2023-09-06 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
US20230096517A1 (en) * 2020-02-25 2023-03-30 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
EP4121043A4 (en) * 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2021198966A1 (en) * 2020-03-31 2021-10-07 Orum Therapeutics, Inc. Conjugates
JP2023520940A (ja) * 2020-04-09 2023-05-22 ユーブラス バイオセラピューティクス インコーポレーテッド 標的プロテアーゼ分解（ｔｅｄ）プラットフォーム
WO2021205391A1 (zh) 2020-04-09 2021-10-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
WO2022043930A2 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
WO2022042707A1 (en) * 2020-08-27 2022-03-03 Cullgen (Shanghai) , Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12391663B2 (en) 2021-01-13 2025-08-19 Monte Rosa Therapeutics Ag Isoindolinone compounds
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
CN112979657A (zh) * 2021-02-03 2021-06-18 福建医科大学 一种靶向降解Hsp90蛋白的化合物及其制备方法与应用
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2022185260A1 (en) 2021-03-04 2022-09-09 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
WO2022223033A1 (zh) 2021-04-23 2022-10-27 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US11878968B2 (en) 2021-07-09 2024-01-23 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate IKZF2
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US12156916B2 (en) 2022-09-07 2024-12-03 Arvinas Operations, Inc. Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025096855A1 (en) 2023-11-02 2025-05-08 Kumquat Biosciences Inc. Degraders and uses thereof

Also Published As

Publication number Publication date
AU2021232732A1 (en) 2021-10-14
AU2017246453A1 (en) 2018-11-08
JP7001614B2 (ja) 2022-02-03
US20190119289A1 (en) 2019-04-25
US20210002289A1 (en) 2021-01-07
CA3020281A1 (en) 2017-10-12
EP3440082A1 (en) 2019-02-13
JP2022050469A (ja) 2022-03-30
CN109311900A (zh) 2019-02-05
JP2019513746A (ja) 2019-05-30
US10759808B2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
EP3440082A1 (en) Monofunctional intermediates for ligand-dependent target protein degradation
AU2009263037B2 (en) Alkynyl alcohols as kinase inhibitors
AU2007292155B2 (en) Imidazole derivative
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
MXPA05000336A (es) Antagonistas del receptor 1 de hormona de concentracion de melanina (mchir).
WO2014027053A1 (en) Benzimidazoles for the treatment of cancer
JP6268276B2 (ja) ＰＥＲＫ阻害剤としての新規なＮ（２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン−５−イル）−４−キナゾリンアミン誘導体およびＮ−（２，３−ジヒドロ−１Ｈ−インドール−５−イル）−４−キナゾリンアミン誘導体
KR101920472B1 (ko) 오렉신 수용체 길항제로서의 피페리딘 유도체
JP2021504464A (ja) 新規ブラジキニンｂ２受容体アンタゴニスト
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
AU2016345244B2 (en) Pyrrolidine derivatives
KR20200083529A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
KR101576343B1 (ko) 피라졸리딘-3-온 유도체
CA2589433A1 (en) Inducible nitric oxide synthase dimerization inhibitors
CA3187092A1 (en) Benzimidazole derivatives, preparation method therefor and medical use thereof
JPWO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
WO2022228413A1 (zh) 一种抑制细胞程序性死亡的化合物及其制备方法
KR20200040799A (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
ES2870303T3 (es) Antagonistas de los receptores de CGRP
KR20200100615A (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
TW202400148A (zh) 作為trpa1抑制劑之吡啶酮化合物
JP2008503556A (ja) オキシトシンアンタゴニストとしての置換ジケトピペラジン
JP7462683B2 (ja) 皮膚疾患を処置するためのブラジキニン（ｂｋ）ｂ２受容体アンタゴニストとしての１－（（ｓ）－１－（３－クロロ－５－フルオロ－２－（（４－（１ｈ－ピラゾール－１－イル）－２－メチルキノリン－８－イルオキシ）メチル）フェニル）エチル）－イミダゾリジン－２，４－ジオン誘導体および関連化合物
CN120835783A (zh) 作为trpa1抑制剂的双环酰亚胺化合物
WO2025245351A1 (en) Substituted aryl sulfonamides and compositions and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3020281

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018552788

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017718291

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017246453

Country of ref document: AU

Date of ref document: 20170406

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017718291

Country of ref document: EP

Effective date: 20181106

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17718291

Country of ref document: EP

Kind code of ref document: A1